← FUJIFILM overview

FUJIFILM vs Guangzhou Wondfo Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

FUJIFILM Holdings Corp (4901.JP)

Q3 2026
▲2▼1

Fujifilm's mixed quarter: record sales but profit hit; printer spin-off weighed

  • Q1 profit drops 30% on Bio CDMO costs and restructuring Fujifilm's first-quarter net income fell 30% to ¥37.4 billion even as revenue hit a record ¥826.5 billion. Higher fixed costs in the Bio CDMO business, one-time restructuring charges at Business Innovation, and rising raw material prices squeezed operating profit, and the Healthcare segment swung to a loss. Management cut its full-year Healthcare profit guidance, a clear drag on the stock.

    This is the single biggest new financial event for 4901.JP, directly explaining why earnings and guidance disappointed.

  • Printer business spin-off considered within 2-3 years Fujifilm said it is considering spinning off Fujifilm Business Innovation, its office printer and multifunction device unit, in two to three years and listing it separately. That unit is about 35% of total revenue. A spin-off could unlock value by letting each business focus, but it also shrinks the parent's revenue base and adds uncertainty while details are vague.

    This is a major new strategic move that changes the company's structure and is a key reason investors are reassessing 4901.JP.

  • Nvidia partnership brings AI-powered medical CT systems At Nvidia's Japan AI event, Fujifilm introduced next-generation CT scanners built with Nvidia technology. This ties Fujifilm's medical imaging business to the fast-growing AI healthcare trend, supporting future product demand and reinforcing its technology credentials. The financial impact is not immediate, but it strengthens the long-term growth story for the Healthcare segment.

    It is a new collaboration that supports the investment case for Fujifilm's healthcare and technology businesses.

  • Film camera revival and Google Photos print store expand imaging demand Fujifilm's Utsurundesu disposable camera is seeing renewed popularity, with new waterproof and black-and-white models launching in August. Separately, Fujifilm launched a print store integrated with Google Photos in the U.S., managing the storefront and expanding photo products. Both point to fresh demand in the Imaging segment, a smaller but profitable and brand-building part of the company.

    These are new demand-side developments that show growth in Fujifilm's consumer imaging business.

August 2026
▲2▼1

Fujifilm's mixed quarter: record sales but profit hit; printer spin-off weighed

  • Q1 profit drops 30% on Bio CDMO costs and restructuring Fujifilm's first-quarter net income fell 30% to ¥37.4 billion even as revenue hit a record ¥826.5 billion. Higher fixed costs in the Bio CDMO business, one-time restructuring charges at Business Innovation, and rising raw material prices squeezed operating profit, and the Healthcare segment swung to a loss. Management cut its full-year Healthcare profit guidance, a clear drag on the stock.

    This is the single biggest new financial event for 4901.JP, directly explaining why earnings and guidance disappointed.

  • Printer business spin-off considered within 2-3 years Fujifilm said it is considering spinning off Fujifilm Business Innovation, its office printer and multifunction device unit, in two to three years and listing it separately. That unit is about 35% of total revenue. A spin-off could unlock value by letting each business focus, but it also shrinks the parent's revenue base and adds uncertainty while details are vague.

    This is a major new strategic move that changes the company's structure and is a key reason investors are reassessing 4901.JP.

  • Nvidia partnership brings AI-powered medical CT systems At Nvidia's Japan AI event, Fujifilm introduced next-generation CT scanners built with Nvidia technology. This ties Fujifilm's medical imaging business to the fast-growing AI healthcare trend, supporting future product demand and reinforcing its technology credentials. The financial impact is not immediate, but it strengthens the long-term growth story for the Healthcare segment.

    It is a new collaboration that supports the investment case for Fujifilm's healthcare and technology businesses.

  • Film camera revival and Google Photos print store expand imaging demand Fujifilm's Utsurundesu disposable camera is seeing renewed popularity, with new waterproof and black-and-white models launching in August. Separately, Fujifilm launched a print store integrated with Google Photos in the U.S., managing the storefront and expanding photo products. Both point to fresh demand in the Imaging segment, a smaller but profitable and brand-building part of the company.

    These are new demand-side developments that show growth in Fujifilm's consumer imaging business.

Latest
▲2▼1

Fujifilm's mixed quarter: record sales but profit hit; printer spin-off weighed

  • Q1 profit drops 30% on Bio CDMO costs and restructuring Fujifilm's first-quarter net income fell 30% to ¥37.4 billion even as revenue hit a record ¥826.5 billion. Higher fixed costs in the Bio CDMO business, one-time restructuring charges at Business Innovation, and rising raw material prices squeezed operating profit, and the Healthcare segment swung to a loss. Management cut its full-year Healthcare profit guidance, a clear drag on the stock.

    This is the single biggest new financial event for 4901.JP, directly explaining why earnings and guidance disappointed.

  • Printer business spin-off considered within 2-3 years Fujifilm said it is considering spinning off Fujifilm Business Innovation, its office printer and multifunction device unit, in two to three years and listing it separately. That unit is about 35% of total revenue. A spin-off could unlock value by letting each business focus, but it also shrinks the parent's revenue base and adds uncertainty while details are vague.

    This is a major new strategic move that changes the company's structure and is a key reason investors are reassessing 4901.JP.

  • Nvidia partnership brings AI-powered medical CT systems At Nvidia's Japan AI event, Fujifilm introduced next-generation CT scanners built with Nvidia technology. This ties Fujifilm's medical imaging business to the fast-growing AI healthcare trend, supporting future product demand and reinforcing its technology credentials. The financial impact is not immediate, but it strengthens the long-term growth story for the Healthcare segment.

    It is a new collaboration that supports the investment case for Fujifilm's healthcare and technology businesses.

  • Film camera revival and Google Photos print store expand imaging demand Fujifilm's Utsurundesu disposable camera is seeing renewed popularity, with new waterproof and black-and-white models launching in August. Separately, Fujifilm launched a print store integrated with Google Photos in the U.S., managing the storefront and expanding photo products. Both point to fresh demand in the Imaging segment, a smaller but profitable and brand-building part of the company.

    These are new demand-side developments that show growth in Fujifilm's consumer imaging business.

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Q3 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

August 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

Latest
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.